Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
REGULATORY 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
-
REGULATORY (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
-
REGULATORY Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
-
ACADEMIA Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
-
ORGANIZATION JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
-
REGULATORY Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
-
REGULATORY Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
-
ORGANIZATION JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
-
BUSINESS FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
-
BUSINESS Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
-
BUSINESS Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
-
BUSINESS AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
-
REGULATORY Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
-
REGULATORY 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
-
REGULATORY Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
-
REGULATORY Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
-
BUSINESS FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
-
BUSINESS FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
-
BUSINESS FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…